Share on LinkedInShare on LinkedIn

ARTICLE · 03 JUNE 2024

Launch Of pCPA Temporary Access Process

On April 5, 2024, the pan-Canadian Pharmaceutical Alliance (pCPA) announced that it was ready to accept drugs through the pCPA Temporary Access Process (pTAP) (see our previous article regarding the consultation).

CanadaFood, Drugs, Healthcare, Life Sciences

On April 5, 2024, the pan-Canadian Pharmaceutical Alliance (pCPA) announced that it was ready to accept drugs through the pCPA Temporary Access Process (pTAP) (see our previous article regarding the consultation).

The purpose of the pTAP, which will apply to drug products that follow the Canadian Drug Agency's (formerly Canadian Agency for Drugs and Technologies in Health (CADTH)) time-limited reimbursement recommendation pathway, is to allow patients temporary access to drugs with promising early results while further clinical evidence is collected. Full details of the program are available on the pTAP webpage. pTAP is a pilot project and will be subject to regular monitoring and assessment. Currently, there is one drug that is in active pTAP negotiation, EPKINLY (epcoritamab).

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.

See more popular content from